Catalent signs commercial supply agreement with Blueprint Medicines

Image source: Blueprint Medicines Corp.

The agreement comes hot on the heels of FDA approval of Gavreto — Blueprint Medicines' new treatment for lung cancer

The new therapy is indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

Gavreto is a once-daily oral RET-targeted therapy that is designed to selectively and potently inhibit RET alterations that drive many cancer types, including approximately 1–2% of patients with metastatic NSCLC.

Currently, RET is one of seven NSCLC biomarkers that can be targeted with an FDA-approved therapy.

This agreement will continue Catalent’s involvement in the Gavreto program, which has been supported by Catalent’s Nottingham, UK, site since 2015.

Jonathan Arnold, President of Oral and Specialty Delivery at Catalent commented: “The expertise that our scientists in Nottingham brought to the development program supported Blueprint Medicines’ efforts to rapidly gain regulatory approval, and through expedient tech transfer within our company’s global network, our team in Kansas City can effectively support commercial supply.”

In February 2020, Catalent announced a commercial supply agreement for Blueprint Medicines’ Ayvakit (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumour harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.